287 related articles for article (PubMed ID: 33340073)
1. A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy.
Fusco V; Cabras M; Erovigni F; Dell'Acqua A; Arduino PG; Pentenero M; Appendino P; Basano L; Ferrera FD; Fasciolo A; Caka M; Migliario M
Med Oral Patol Oral Cir Bucal; 2021 Jul; 26(4):e466-e473. PubMed ID: 33340073
[TBL] [Abstract][Full Text] [Related]
2. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
3. A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab.
Bracchi P; Zecca E; Brunelli C; Miceli R; Tinè G; Maniezzo M; Lo Dico S; Caputo M; Shkodra M; Caraceni AT
Cancer Med; 2023 Sep; 12(17):18317-18326. PubMed ID: 37559413
[TBL] [Abstract][Full Text] [Related]
4. Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement.
Sánchez-Gallego Albertos C; Del Castillo Pardo de Vera JL; Viejo Llorente A; Cebrián Carretero JL
Med Oral Patol Oral Cir Bucal; 2021 Nov; 26(6):e684-690. PubMed ID: 34704981
[TBL] [Abstract][Full Text] [Related]
5. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
[TBL] [Abstract][Full Text] [Related]
6. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
Ikesue H; Mouri M; Tomita H; Hirabatake M; Ikemura M; Muroi N; Yamamoto S; Takenobu T; Tomii K; Kawakita M; Katoh H; Ishikawa T; Yasui H; Hashida T
Support Care Cancer; 2021 Aug; 29(8):4763-4772. PubMed ID: 33527228
[TBL] [Abstract][Full Text] [Related]
7. Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study.
Hallmer F; Bjarnadottir O; Götrick B; Malmström P; Andersson G
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Sep; 130(3):252-257. PubMed ID: 32536575
[TBL] [Abstract][Full Text] [Related]
8. Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study.
Hata H; Imamachi K; Ueda M; Matsuzaka M; Hiraga H; Osanai T; Harabayashi T; Fujimoto K; Oizumi S; Takahashi M; Yoshikawa K; Sato J; Yamazaki Y; Kitagawa Y
Support Care Cancer; 2022 May; 30(5):4505-4514. PubMed ID: 35113225
[TBL] [Abstract][Full Text] [Related]
9. Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ).
Otto S; Aljohani S; Fliefel R; Ecke S; Ristow O; Burian E; Troeltzsch M; Pautke C; Ehrenfeld M
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34065104
[TBL] [Abstract][Full Text] [Related]
10. Is the prevalence of the medication-related osteonecrosis of the jaws underestimated, evaluation in oncological and non-oncological disease.
Galis B; Zajko J; Hirjak D; Vanko L; Kupcova I; Jurkemik J; Gengelova P; Mikuskova K; Halmova K; Riznic M; Czako L
Bratisl Lek Listy; 2017; 118(12):724-731. PubMed ID: 29322803
[TBL] [Abstract][Full Text] [Related]
11. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
Kajizono M; Sada H; Sugiura Y; Soga Y; Kitamura Y; Matsuoka J; Sendo T
Biol Pharm Bull; 2015; 38(12):1850-5. PubMed ID: 26632176
[TBL] [Abstract][Full Text] [Related]
12. Multiple myeloma identified within the same site of the mandible with medication-related osteonecrosis of jaw: An unusual case report.
Wu XH; Chen SW
Medicine (Baltimore); 2023 Jul; 102(29):e34260. PubMed ID: 37478232
[TBL] [Abstract][Full Text] [Related]
13. Multiple myeloma and chemical maxillary osteonecrosis. Can both occur simultaneously?
Junquera S; Álvarez-Yagüe E; Junquera L; Ugalde R; Rúa L
J Stomatol Oral Maxillofac Surg; 2020 Nov; 121(5):523-526. PubMed ID: 31863926
[TBL] [Abstract][Full Text] [Related]
14. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.
Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
Support Care Cancer; 2022 Mar; 30(3):2341-2348. PubMed ID: 34738163
[TBL] [Abstract][Full Text] [Related]
15. Dental pathologies in tumor patients with bone metastases or multiple myeloma scheduled for antiresorptive therapy.
Laimer J; Hechenberger M; Müller D; Walch B; Kolk A; Schnabl D; Schomaker M; Bruckmoser E
Future Oncol; 2021 Jul; 17(21):2705-2711. PubMed ID: 33880956
[No Abstract] [Full Text] [Related]
16. Prevalence, Incidence Rate, and Risk Factors of Medication-Related Osteonecrosis of the Jaw in Patients With Osteoporosis and Cancer: A Nationwide Population-Based Study in Japan.
Ishimaru M; Ono S; Morita K; Matsui H; Hagiwara Y; Yasunaga H
J Oral Maxillofac Surg; 2022 Apr; 80(4):714-727. PubMed ID: 35033505
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid.
Wei LY; Kok SH; Lee YC; Chiu WY; Wang JJ; Cheng SJ; Chang HH; Lee JJ
J Formos Med Assoc; 2021 Aug; 120(8):1572-1580. PubMed ID: 33309430
[TBL] [Abstract][Full Text] [Related]
18. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis.
Dos Santos Ferreira L; Abreu LG; Calderipe CB; Martins MD; Schuch LF; Vasconcelos ACU
Osteoporos Int; 2021 Dec; 32(12):2449-2459. PubMed ID: 34331067
[TBL] [Abstract][Full Text] [Related]
19. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
20. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
